CA3043938A1 - Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof - Google Patents

Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof Download PDF

Info

Publication number
CA3043938A1
CA3043938A1 CA3043938A CA3043938A CA3043938A1 CA 3043938 A1 CA3043938 A1 CA 3043938A1 CA 3043938 A CA3043938 A CA 3043938A CA 3043938 A CA3043938 A CA 3043938A CA 3043938 A1 CA3043938 A1 CA 3043938A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
alkyl
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3043938A
Other languages
English (en)
French (fr)
Inventor
Kyle W. H. Chan
Paul E. Erdman
Leah Fung
Frank Mercurio
Robert Sullivan
Eduardo Torres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioTheryX Inc
Original Assignee
BioTheryX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioTheryX Inc filed Critical BioTheryX Inc
Publication of CA3043938A1 publication Critical patent/CA3043938A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3043938A 2016-12-21 2017-12-19 Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof Abandoned CA3043938A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662437400P 2016-12-21 2016-12-21
US62/437,400 2016-12-21
US201762485563P 2017-04-14 2017-04-14
US62/485,563 2017-04-14
US201762538203P 2017-07-28 2017-07-28
US62/538,203 2017-07-28
PCT/US2017/067353 WO2018118947A1 (en) 2016-12-21 2017-12-19 Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Publications (1)

Publication Number Publication Date
CA3043938A1 true CA3043938A1 (en) 2018-06-28

Family

ID=60991575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043938A Abandoned CA3043938A1 (en) 2016-12-21 2017-12-19 Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Country Status (13)

Country Link
US (4) US10040804B2 (enExample)
EP (1) EP3559005A1 (enExample)
JP (1) JP2020504711A (enExample)
KR (1) KR20190093205A (enExample)
CN (1) CN110099907A (enExample)
AU (1) AU2017382176A1 (enExample)
CA (1) CA3043938A1 (enExample)
IL (1) IL267323A (enExample)
MX (1) MX387646B (enExample)
RU (1) RU2771166C2 (enExample)
TW (2) TW201835089A (enExample)
WO (1) WO2018118947A1 (enExample)
ZA (1) ZA201903479B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス， インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
US10584133B2 (en) * 2018-03-30 2020-03-10 Biotheryx, Inc. Thienopyrimidinone compounds
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
US11191769B2 (en) * 2018-06-13 2021-12-07 Biotheryx, Inc. Fused thiophene compounds
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
WO2020160192A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
FR3092581A1 (fr) * 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
CN114502543A (zh) * 2019-05-24 2022-05-13 拜欧斯瑞克斯公司 靶向蛋白化合物、其药物组合物及治疗应用
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202124374A (zh) * 2019-09-13 2021-07-01 美商拜歐斯瑞克斯公司 Ras蛋白降解劑、其醫藥組合物及其治療應用
JP7629459B2 (ja) 2019-11-19 2025-02-13 ブリストル－マイヤーズ スクイブ カンパニー Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
EP4681715A3 (en) 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
MX2022009308A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de estos.
BR112022016901A2 (pt) 2020-02-26 2022-12-06 Cullgen Shanghai Inc Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022072538A1 (en) * 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
CN122562781A (zh) * 2020-10-07 2026-08-14 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
PE20231941A1 (es) 2021-04-06 2023-12-05 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
US12662467B2 (en) 2022-04-18 2026-06-23 BioThery X, Inc. Isoindolinones, pharmaceutical compositions, and therapeutic applications
EP4511128A1 (en) 2022-04-20 2025-02-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
IL316803A (en) 2022-06-06 2025-01-01 C4 Therapeutics Inc Bicyclic glutarimide-modified cervalon-binding agents
JP2025531869A (ja) * 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
WO2024096753A1 (en) 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
CN122228262A (zh) 2023-11-02 2026-06-16 金橘生物科技公司 降解剂及其用途
WO2025240386A1 (en) * 2024-05-13 2025-11-20 Saint Joseph's University Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
TW202617734A (zh) * 2024-06-21 2026-05-01 大陸商杭州中美華東製藥有限公司 Gspt1降解劑化合物、包含其的藥物組合物和用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5585377A (en) 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
DE4023048A1 (de) 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES2118941T3 (es) 1992-02-21 1998-10-01 Alcon Lab Inc Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.
US5420923A (en) 1993-02-16 1995-05-30 Scientific-Atlanta, Inc. Addressed messaging in a cable television system
US5334596A (en) 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
CA2188772A1 (en) 1994-06-08 1995-12-14 Balreddy Kamireddy Cyclic sulfonamide herbicides
AU3619795A (en) 1994-10-11 1996-05-02 Takeda Chemical Industries Ltd. Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors
TR199801665T2 (xx) 1996-02-26 1998-12-21 Advanced Research & Technology Institute Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�.
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
JPH10264532A (ja) 1997-03-24 1998-10-06 Fuji Photo Film Co Ltd 感熱記録材料
AU753020B2 (en) 1998-04-30 2002-10-03 Sumitomo Chemical Company, Limited Method for giving resistance to weed control compounds to plants
US6906245B1 (en) 1998-04-30 2005-06-14 Sumitomo Chemical Company, Limited Method for producing transgenic plants resistant to weed control compounds which disrupt the porphyrin pathways of plants
JP2000159761A (ja) 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
JP4821036B2 (ja) 1999-10-29 2011-11-24 住友化学株式会社 除草剤耐性植物
JP4821038B2 (ja) 1999-10-29 2011-11-24 住友化学株式会社 除草剤耐性植物
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
JP2004018434A (ja) 2002-06-14 2004-01-22 Mitsui Chemicals Inc 新規なフッ素化イミド化合物、および該化合物を用いた電子写真感光体、電子写真装置、有機電界発光素子
PT1578741E (pt) 2002-12-23 2011-10-17 4Sc Ag Compostos aromáticos como agentes antiinflamatórios, imunoreguladores e antiproliferativos
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CN100398534C (zh) 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
EP1817025A2 (en) 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
DK2061765T3 (en) 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CN101186611B (zh) 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
JP2008273924A (ja) 2007-03-30 2008-11-13 Meiji Seika Kaisha Ltd ２位チエニルカルバペネム誘導体
KR101128943B1 (ko) 2007-04-13 2012-03-27 주식회사 엘지화학 디옥시피롤기를 포함하는 헤테로고리 화합물 및 이를이용한 유기 전자 소자
CN102245600A (zh) 2008-10-08 2011-11-16 百时美施贵宝公司 吡咯烷酮黑色素浓集激素受体-1拮抗剂
KR20110093841A (ko) 2008-11-07 2011-08-18 4에스체 악티엔게젤샤프트 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
ES2537190T3 (es) 2010-09-01 2015-06-03 Gilead Connecticut, Inc. Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas
US20120085992A1 (en) 2010-09-30 2012-04-12 The Regents Of The University Of California Furan Conjugated Polymers Useful for Photovoltaic Applications
WO2012082893A2 (en) 2010-12-15 2012-06-21 Plextronics, Inc. Fluoro monomers, oligomers, and polymers for inks and organic electronic devices
JP2014517820A (ja) 2011-04-15 2014-07-24 ジョージア テック リサーチ コーポレーション ナフタレンジイミドのスタンニル誘導体及び関連組成物並びに方法
ITMI20110881A1 (it) 2011-05-18 2012-11-19 E T C Srl Materiale semiconduttore organico
WO2013052153A1 (en) 2011-10-05 2013-04-11 Georgia Tech Research Corporation Blends of organic semiconductor compounds and electrically insulating amorphous polymers, methods and devices
JP2014047192A (ja) 2012-09-03 2014-03-17 Sumitomo Chemical Co Ltd 化合物、並びに、該化合物を含有する有機半導体材料、有機半導体素子
JP2014047196A (ja) 2012-09-03 2014-03-17 Sumitomo Chemical Co Ltd 化合物及び高分子化合物、並びに、該化合物又は該高分子化合物を含有する有機半導体材料及び該有機半導体材料を用いた有機半導体素子
CN103664916B (zh) 2012-09-12 2016-08-24 中国科学院化学研究所 基于联噻吩亚二吡咯及其衍生物的共轭小分子材料及其制备方法与应用
ITMI20121691A1 (it) 2012-10-09 2014-04-10 E T C Srl Materiale semiconduttore organico
ITMI20121939A1 (it) 2012-11-15 2014-05-16 E T C Srl Materiale organico semiconduttore
ITMI20121952A1 (it) 2012-11-16 2014-05-17 E T C Srl Materiale semiconduttore organico
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
JP2014185147A (ja) 2013-02-22 2014-10-02 Mitsubishi Chemicals Corp イミド縮合環化合物及びイミド縮合環化合物の製造方法
JP6248400B2 (ja) 2013-03-15 2017-12-20 株式会社リコー 感光体及び画像形成装置
JP2015013989A (ja) 2013-06-05 2015-01-22 三菱化学株式会社 コポリマー、半導体層形成用組成物、有機電子デバイス及び太陽電池モジュール
WO2014204082A1 (ko) 2013-06-20 2014-12-24 경상대학교산학협력단 유기 반도체 화합물, 이의 제조방법 및 이를 채용한 유기 태양전지
KR101595919B1 (ko) 2013-08-30 2016-02-29 한국과학기술연구원 전도성 유기 반도체 화합물 및 이를 포함하는 유기태양전지
US9809594B2 (en) 2013-09-10 2017-11-07 University Of Washington Through Its Center For Commercialization Non-fullerene electron acceptors for organic photovoltaic devices
KR101732220B1 (ko) 2014-03-31 2017-05-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 태양 전지
CN105294536B (zh) 2014-06-30 2018-06-29 中国科学院上海有机化学研究所 一种制备3-亚氨基异吲哚啉酮类化合物的方法
AU2015305449B2 (en) * 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CN104230953B (zh) 2014-08-25 2016-08-17 中国科学院上海有机化学研究所 含2-(1,3-二硫/硒-2-亚基)乙氰共轭结构单元的萘二酰亚胺及其衍生物
WO2016061751A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
CN105693745B (zh) 2014-11-27 2019-07-05 中国科学院苏州纳米技术与纳米仿生研究所 有机π-共轭化合物、其制备方法及应用
AU2016266942B2 (en) 2015-05-22 2018-10-18 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス， インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Also Published As

Publication number Publication date
CN110099907A (zh) 2019-08-06
MX387646B (es) 2025-03-18
US20180298027A1 (en) 2018-10-18
ZA201903479B (en) 2021-09-29
IL267323A (en) 2019-08-29
RU2771166C2 (ru) 2022-04-27
US10336771B2 (en) 2019-07-02
AU2017382176A1 (en) 2019-05-30
RU2019115392A (ru) 2021-01-22
MX2019007434A (es) 2019-08-16
TW202120514A (zh) 2021-06-01
US20190322683A1 (en) 2019-10-24
JP2020504711A (ja) 2020-02-13
US10040804B2 (en) 2018-08-07
TW201835089A (zh) 2018-10-01
WO2018118947A1 (en) 2018-06-28
TWI756957B (zh) 2022-03-01
US20210139500A1 (en) 2021-05-13
US20180170948A1 (en) 2018-06-21
US10889593B2 (en) 2021-01-12
EP3559005A1 (en) 2019-10-30
KR20190093205A (ko) 2019-08-08
US11345714B2 (en) 2022-05-31
RU2019115392A3 (enExample) 2021-05-14

Similar Documents

Publication Publication Date Title
US11345714B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US10857155B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
CA3101335C (en) Fused thiophene compounds
CA3101338A1 (en) Aminoamide compounds
CN113423701A (zh) 取代的异吲哚啉酮
IL255589A (en) Compounds targeting proteins, preparations, methods and uses
CA3094988A1 (en) Thienopyrimidinone compounds
WO2019173224A1 (en) Deuterated compounds and chimeras and uses thereof
EA039447B1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
KR20180050408A (ko) 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211123

FZDE Discontinued

Effective date: 20240501